Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409258 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1PKMTDP1MEN1 | |
| SCHEMBL31395128 | 0.86 | KDM4E (0.33) | KDM4E | |
| SCHEMBL31273758 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1PKMTDP1MEN1 | |
| SCHEMBL15932539 | 0.84 | KDM4E (0.39) | KDM4EALDH1A1PKMTDP1TSHR | |
| SCHEMBL31274004 | 0.84 | KDM4E (0.39) | KDM4EALDH1A1PKMTDP1TSHR | |
| SCHEMBL14280195 | 0.83 | KDM4E (0.42) | KDM4EALDH1A1PKMTDP1MEN1 | |
| SCHEMBL3649763 | 0.82 | KDM4E (0.38) | KDM4EALDH1A1PKMTDP1MEN1 | |
| SCHEMBL3645419 | 0.82 | KDM4E (0.38) | KDM4EALDH1A1PKMTDP1MEN1 | |
| SCHEMBL145809 | 0.78 | KDM4E (0.38) | KDM4EALDH1A1PKMTDP1MEN1 | |
| SCHEMBL17934494 | 0.77 | KDM4E (0.45) | KDM4EALDH1A1PKMTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054493-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240018298-A1 | OLEFINIC COMPOSITIONS COMPRISING HYDROCARBON RESINS | ExxonMobil Product Solutions Company | 2024-01-18 | — | — | US | disclosed |
| WO-2023049857-A1 | HYBRID COMPOSITIONS COMPRISING OLEFINIC COMPOSITIONS AND RESIN COMPOSITIONS POLYMERIZABLE BY ADDITION OR CONDENSATION POLYMERIZATION REACTIONS | MATERIA, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-3426245-B1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220127491-A1 | COATING COMPOSITIONS | ExxonMobil Product Solutions Company | 2022-04-28 | — | — | US | disclosed |
| US-20210347935-A1 | POLYMERS FOR SPECIALTY APPLICATIONS | ExxonMobil Product Solutions Company | 2021-11-11 | — | — | US | disclosed |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-07-29 | — | — | US | disclosed |
| US-10934306-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200199143-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-06-25 | — | — | US | disclosed |
| WO-2020123946-A1 | COATING COMPOSITIONS | MATERIA, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020072776-A1 | POLYMERS FOR SPECIALTY APPLICATIONS | MATERIA, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10179792-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-8211984-B2 | Ring-opening metathesis polymer, hydrogenated product thereof, method for preparing the same, and use thereof | MITSUI CHEMICALS, INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-7851575-B2 | Polycyclic polymers containing pendant ion conducting moieties | PROMERUS LLC (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090215974-A1 | RING-OPENING METATHESIS POLYMER, HYDROGENATED PRODUCT THEREOF, METHOD FOR PREPARING THE SAME, AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2045280-A1 | RING-OPENING METATHESIS POLYMERS, PRODUCTS OF HYDROGENATION THEREOF, PROCESS FOR PRODUCTION OF THE SAME AND USES THEREOF | Mitsui Chemicals, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080242750-A1 | Polycyclic polymers containing pendant ion conducting moieties | PROMERUS LLC | 2008-10-02 | — | — | US | disclosed |
| US-20080027246-A1 | Process for forming perfluorinated-alkyl sulfonamide substituted norbornene-type monomers | PROMERUS, LLC | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179792-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KDM4E 1148/4885ALDH1A1 3634/4885PKM 2707/4885 |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KDM4E 1148/4885ALDH1A1 3634/4885PKM 2707/4885 |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KDM4E 1148/4885ALDH1A1 3634/4885PKM 2707/4885 |
| US-20080027246-A1 | Process for forming perfluorinated-alkyl sulfonamide substituted norbornene-type monomers | PFAS, FLNA, FLNB | KDM4E 3732/4885ALDH1A1 351/4885PKM 2557/4885 |
| US-12054493-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KDM4E 1148/4885ALDH1A1 3634/4885PKM 2707/4885 |
| US-20200199143-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KDM4E 1148/4885ALDH1A1 3634/4885PKM 2707/4885 |
| US-10934306-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KDM4E 1148/4885ALDH1A1 3634/4885PKM 2707/4885 |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KDM4E 1148/4885ALDH1A1 3634/4885PKM 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.